BridgeBio Pharma (BBIO) Current Deferred Revenue (2019 - 2026)

BridgeBio Pharma has disclosed Current Deferred Revenue across 6 years of filings, most recently posting $6.1 million for Q1 2026.

• Current Deferred Revenue for Q1 2026 came in at $6.1 million, down 47.38% year-over-year; the trailing twelve-month figure through Mar 2026 was $6.1 million (down 47.38% YoY), and the FY2025 annual result was $7.2 million, down 50.77% from the prior year.
• Current Deferred Revenue came in at $6.1 million for Q1 2026 at BridgeBio Pharma, down from $7.2 million in the prior quarter.
• In the past five years, Current Deferred Revenue ranged from a high of $100.0 million in Q2 2024 to a low of $6.1 million in Q4 2023.
• The 5-year median for Current Deferred Revenue is $9.8 million (2025), against an average of $20.5 million.
• Across the five-year window, Current Deferred Revenue slumped 93.1% in 2023 and jumped 1510.31% in 2024, its largest moves.
• BridgeBio Pharma's Current Deferred Revenue stood at $19.8 million in 2022, then tumbled by 69.21% to $6.1 million in 2023, then soared by 139.57% to $14.6 million in 2024, then slumped by 50.77% to $7.2 million in 2025, then slipped by 14.95% to $6.1 million in 2026.
• The last three Current Deferred Revenue figures came in at $6.1 million (Q1 2026), $7.2 million (Q4 2025), and $9.1 million (Q3 2025), per Business Quant data.